BridgeBio Pharma, Inc. reported $713M of revenue over the trailing twelve months, +202% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $713M (to Q2 2026). Net income: −$702M, trailing twelve months to Q2 2026. Free cash flow: −$435M, trailing twelve months to Q2 2026. Operating margin: −77%, trailing twelve months to Q2 2026.

BBIOBridgeBio Pharma, Inc.

Healthcare

$65.35+25% 1Y

$65.35

$49.0052 weeks$85.86

BBIO as reported

BridgeBio Pharma, Inc. reported $713M of revenue over the trailing twelve months, +202% on the year before. 10 reported series are charted on this page, each one as filed.

$713M

Revenue, trailing twelve months · to Q2 2026 · +202% against the twelve months before

Net income: −$702M
Net income · −11% year on year · trailing twelve months to Q2 2026
Free cash flow: −$435M
Free cash flow · −34% year on year · trailing twelve months to Q2 2026
Operating margin: −77%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BBIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$713M	+202%	Q2 2026
Net income	−$702M	−11%	Q2 2026
EPS	−$3.56	−13%	Q2 2026
Gross margin	95%	n/a	Q2 2026
Operating margin	−77%	n/a	Q2 2026
Net margin	−107%	n/a	Q2 2026
ROE	34%	n/a	Q2 2026
ROA	−67%	n/a	Q2 2026
ROIC	72%	n/a	Q2 2026
Free cash flow	−$435M	−34%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.